ライフサイエンスコーパス: lung disease

1 IPF) is a progressive and fatal interstitial lung disease.

2 e treatment of acute lung injury and chronic lung disease.

3 ial effects on wheezing, asthma, and chronic lung disease.

4 e components further differ depending on the lung disease.

5 udy has yet examined the mycobiome in fungal lung disease.

6 te investigation of subclinical interstitial lung disease.

7 uce the risk of progressing to more advanced lung disease.

8 ects of human lung development and pediatric lung disease.

9 important pathobiological factor in early CF lung disease.

10 s, and 1 patient died of severe interstitial lung disease.

11 , destructive skin lesions, and interstitial lung disease.

12 tive outcome measures that capture and track lung disease.

13 jury and in human tissues from subjects with lung disease.

14 ted with abnormal lung perfusion in early CF lung disease.

15 find that SARS-CoV infection causes enhanced lung disease.

16 s no other family history of asthma or other lung disease.

17 that are critical for protection from severe lung disease.

18 mic toxicity in patients with refractory MAC lung disease.

19 opathy, cerebrovascular disease, and chronic lung disease.

20 progression of tissue injury seen in chronic lung disease.

21 development may set the stage for subsequent lung disease.

22 humanized model for pre-clinical studies of lung disease.

23 d potential therapeutic targets for neonatal lung disease.

24 change in structure associated with advanced lung disease.

25 infants who subsequently went on to develop lung disease.

26 expressing mice, a well-established model of lung disease.

27 has a high mortality associated with severe lung disease.

28 ary hypertension due to left-sided heart and lung disease.

29 healthy children) from the progression of CF lung disease.

30 so, whether it is associated with subsequent lung disease.

31 damage in the etiology of flavorings-related lung disease.

32 totype of chronic, progressive, and fibrotic lung disease.

33 utic target in the management of RSV-induced lung disease.

34 ent for the diagnosis of diffuse parenchymal lung disease.

35 hanges in these histologic features indicate lung disease.

36 n health and as altered by acute and chronic lung disease.

37 setting of scleroderma-related interstitial lung disease.

38 ay generations were observed in end-stage CF lung disease.

39 d through endoscopy from 14 patients without lung disease.

40 d pathological signs indicative of end-stage lung disease.

41 as possible therapeutic targets for treating lung disease.

42 5) has been consistently linked to heart and lung disease.

43 hen they are smear-negative or lack cavitary lung disease.

44 ), with most due to progressive interstitial lung disease.

45 by the investigator was due to interstitial lung disease.

46 individuals as well as patients with chronic lung disease.

47 pulmonary fibrosis (IPF) is a deadly chronic lung disease.

48 structive pulmonary disease and occupational lung disease.

49 05 benchmark for all outcomes except chronic lung disease.

50 increase in the work of breathing in chronic lung disease.

51 (CFTR) channel, which can result in chronic lung disease.

52 these chemokine pathways could help improve lung disease.

53 lung physiology consistent with interstitial lung disease.

54 for EHF in regulating epithelial function in lung disease.

55 SPNs in populations with endemic infectious lung disease.

56 cularly phenotype patients with interstitial lung disease.

57 tational age, birth weight, and less chronic lung disease.

58 tion for reducing the burden of occupational lung diseases.

59 acute and chronic inflammatory and fibrotic lung diseases.

60 has been linked to the worsening of ongoing lung diseases.

61 rvention and/or prevention of silica-induced lung diseases.

62 during wound healing and is dysregulated in lung diseases.

63 ypoxic PH and potentially other inflammatory lung diseases.

64 inform the development of new therapies for lung diseases.

65 fibrosis is the hallmark of the interstitial lung diseases.

66 ould underlie the chronicity of inflammatory lung diseases.

67 n cystic fibrosis (CF) and other obstructive lung diseases.

68 ular regulation and function of autophagy in lung diseases.

69 s to the pathogenesis and treatment of human lung diseases.

70 thological fibroblasts and myofibroblasts in lung diseases.

71 thogenesis of Th2-driven asthma and allergic lung diseases.

72 portant trigger of acute episodes of chronic lung diseases.

73 re of cystic fibrosis (CF) and other chronic lung diseases.

74 BEC) is essential for understanding numerous lung diseases.

75 of patients with other progressive fibrotic lung diseases.

76 f transport in persons with muco-obstructive lung diseases.

77 le of the respiratory epithelium in multiple lung diseases.

78 D (Global Initiative for Chronic Obstructive Lung Disease) 0-4 was as follows: 41.8 (47.7), 53.8 (57.

79 l class IV (1.25; 1.03-1.52), severe chronic lung disease (1.67; 1.35-2.05), nonfemoral access site (

80 amyotrophic lateral sclerosis, 44 (4.5%) had lung disease, 26 (2.6%) had heart disease, and 9 (0.9%)

81 lowest rates seen among patients with severe lung disease (51.4%), those undergoing dialysis (47.7%),

82 apors are associated with flavorings-related lung disease, a potentially fatal airway disease.

83 s in breath samples can potentially indicate lung disease activity and help in the study of airway in

84 To model a chronic lung disease, ADA(-/-) mice were used.

85 ATIONALE: Mechanisms contributing to chronic lung disease after preterm birth are incompletely unders

86 nd Severe Sepsis Risk Score included chronic lung disease, age 75 years or older, peripheral artery d

87 England, and South Atlantic for interstitial lung disease; along the southern half of the Mississippi

88 ere dysfunction and humans with interstitial lung disease also accumulate excess chitin polymers in t

89 Chronic lung disease alters these factors.

90 urvey to determine the prevalence of chronic lung disease among adults 18 years or older in Malawi, u

91 hage, necrotizing enterocolitis, and chronic lung disease among infants less than 33 weeks' gestation

92 ears) including 4 patients with interstitial lung disease and 3 patients with cutaneous clinical feat

93 ears) including 4 patients with interstitial lung disease and 3 patients with cutaneous clinical feat

94 reviewed consecutive patients with end-stage lung disease and a height of 65 inches or less who under

95 Patients with interstitial lung disease and acute respiratory failure have a poor p

96 saving option for patients with interstitial lung disease and acute respiratory failure provided they

97 e analysis of all patients with interstitial lung disease and acute respiratory failure treated with

98 e ligands during infection leads to enhanced lung disease and altered wound healing dynamics.

99 lls (iPSCs) would provide valuable models of lung disease and facilitate precision therapies for airw

100 , preterm infants frequently develop chronic lung disease and have a significantly increased risk of

101 multidisciplinary diagnosis of interstitial lung disease and may prove useful in the diagnosis of IP

102 y the investigators, one due to interstitial lung disease and one as a result of multiorgan failure t

103 in severe cases can resolve with restrictive lung disease and pleural fibrosis.

104 PD) is characterized by lifelong obstructive lung disease and profound, refractory bronchospasm.

105 ute to understanding the role of exosomes in lung disease and provide suggestions for highly warrante

106 ification of Diseases codes for interstitial lung disease and surgical lung biopsies.

107 ivo contribution of IL-17 in cystic fibrosis lung disease and the therapeutic validity of attenuating

108 to the molecular mechanism of silica-induced lung disease and tumorigeneses.

109 nded sub-pixel contrasts in the diagnosis of lung diseases and beyond.

110 e first introduce representative obstructive lung diseases and examine limitations of currently avail

111 nt in the pathogenesis of cardiovascular and lung diseases and vascular inflammation.

112 l and clinical research networks in fibrotic lung disease, and create a global lung fibrosis initiati

113 esearch and clinical practice in obstructive lung disease, and drug discovery platforms was invited t

114 fore discharge, NDI, moderate-severe chronic lung disease, and severe retinopathy of prematurity.

115 city or echolucency on neuroimaging, chronic lung disease, and stage 3 or higher retinopathy of prema

116 M. africanum and monitored bacterial growth, lung disease, and survival over 292 days.

117 progressive scleroderma-related interstitial lung disease, and the present preference for mycophenola

118 International Union Against Tuberculosis and Lung Disease, and the World Health Organization also par

119 ferential diagnoses from a choice of diffuse lung diseases, and chose likelihoods (censored at 5% and

120 c output from arteriovenous fistula, hypoxic lung diseases, and metabolic derangements associated wit

121 with CHD with renal dysfunction, restrictive lung disease, anemia, and cirrhosis.

122 NDI (aOR, 1.27; 95% CI, 0.78-2.06), chronic lung disease (aOR, 1.36; 95% CI, 0.78-2.39) or severe re

123 hloride levels, failure to thrive (FTT), and lung disease are characteristic features of cystic fibro

124 en lung clearance index and early structural lung disease are unclear.

125 ract infections and exacerbations of chronic lung diseases are commonly caused by nontypeable Haemoph

126 cellular processes that precede or accompany lung diseases are needed.

127 es, the proximal causes of many occupational lung diseases are well understood and they should be ame

128 thogen in patients with cystic fibrosis (CF) lung disease as well as non-CF bronchiectasis and chroni

129 pportive therapy consistent with any serious lung disease, as no specific drugs have been approved as

130 Lymphangioleiomyomatosis (LAM) is a fatal lung disease associated with germline or somatic inactiv

131 e lung disease, the phenotype of obstructive lung disease associated with work-related organic dust e

132 target in the pathogenesis and treatment of lung diseases associated with premature birth.

133 heart catheterization, medications, chronic lung disease, bleeding diathesis, and immunodeficiency.

134 ntial for the treatment of M. intracellulare lung disease, but optimization of treatment regimens is

135 Involvement of gut microbiota in lung diseases by the gut-lung axis has been widely obser

136 5 yr) and the Canadian Cohort of Obstructive Lung Disease (CanCOLD) study (n = 1,551 subjects; study

137 y worldwide, the history of asbestos-induced lung disease casts a long shadow over fibrous materials

138 is (CF) is characterized by early structural lung disease caused by pulmonary infections.

139 ry aspergillosis (IPA) is a life-threatening lung disease caused by the fungus Aspergillus fumigatus,

140 Asthma is a common chronic lung disease characterized by airflow obstruction, airwa

141 is a chronic, progressive and fatal fibrotic lung disease characterized by profound changes in stem c

142 erbate fibrogenic pathways in the setting of lung diseases characterized by epithelial cell dysfuncti

143 ution between 2004 and 2014 for interstitial lung disease, chronic obstructive pulmonary disease, or

144 philic inflammation characterize the chronic lung disease cystic fibrosis (CF).

145 ral mitral regurgitation, moderate or severe lung disease, dialysis, and severe tricuspid regurgitati

146 brosis is a kind of devastating interstitial lung disease due to the limited therapeutic strategies.

147 irway closure has important implications for lung disease, especially asthma; in particular, the pros

148 g (18)F-FDG PET quantification approaches in lung diseases, focusing on methods to account for variat

149 Forty-five experts in interstitial lung disease from 14 countries participated in the onlin

150 Universities Corticosteroids in Obstructive Lung Disease (GLUCOLD) study.

151 or stage 2 Global initiative for Obstructive Lung Disease (GOLD) COPD who had been clinically stable

152 he Global Initiative for Chronic Obstructive Lung Disease (GOLD) spirometric category (1-4) on the ba

153 on Global Initiative for Chronic Obstructive Lung Disease guidelines, 461 patients (17.6%) had mild,

154 3 patients with Mycobacterium intracellulare lung disease had an initial microbiological response and

155 Although the incidence of occupational lung disease has decreased in many countries, in parts o

156 Knowledge of genetic origins of obstructive lung diseases has made inhaled gene therapy an attractiv

157 all parts of the world, left-sided heart and lung diseases have become the most frequent causes of pu

158 status, older age, higher ejection fraction, lung disease, home oxygen use, lower mean aortic valve g

159 sease (HR, 1.20; 95% CI, 1.04-1.39), chronic lung disease (HR, 1.16; 95% CI, 1.01-1.34), and discharg

160 e, recurrent hyponatremia, infantile FTT and lung disease identified deleterious variants in each CA1

161 echanisms underlying dyspnea in interstitial lung disease (ILD) and chronic obstructive pulmonary dis

162 DPO) in patients with fibrosing interstitial lung disease (ILD) and determine whether there are diffe

163 fic signatures across end-stage interstitial lung disease (ILD) cases, (2) characterize ILD subgroups

164 s (IPF) is a progressive, fatal interstitial lung disease (ILD) characterized by abnormal extracellul

165 tional exposures on subclinical interstitial lung disease (ILD) has not been studied.

166 RATIONALE: Interstitial lung disease (ILD) is a heterogeneous group of acute and

167 association is attributable to interstitial lung disease (ILD).

168 Interstitial lung diseases (ILDs) are associated with oxidative stres

169 Progressive fibrotic interstitial lung diseases (ILDs) are characterised by major reductio

170 sm to delay or prevent the development of CF lung disease in a manner independent of CF transmembrane

171 e UK) evaluated cases of diffuse parenchymal lung disease in a two-stage process between Jan 1, and O

172 nce imaging (MRI) were shown to detect early lung disease in CF; however, the relationship between th

173 summarizes what we have learned about early lung disease in children with CF and discusses the impli

174 RATIONALE: Early onset and progression of lung disease in children with cystic fibrosis (CF) indic

175 chest syndrome is a frequent cause of acute lung disease in children with sickle-cell disease.

176 nding of the pathogenesis and progression of lung disease in cystic fibrosis (CF).

177 buting to virus-induced pneumonia and severe lung disease in humans.

178 virus (RSV) are common and can cause severe lung disease in infants and the elderly.

179 F3-independent immune cell dysregulation and lung disease in mice.

180 ations for understanding the pathogenesis of lung disease in obese patients.

181 eful surveillance tool to monitor structural lung disease in preschool and school-age children with C

182 produced modest improvements in radiographic lung disease in subjects with G551D-CFTR mutations.

183 g subclinical Pneumocystis infection induces lung disease in the immunocompetent host.

184 the mechanisms leading to the development of lung disease in the setting of neonatal necrotizing ente

185 biopsies performed annually for interstitial lung disease in the United States, two-thirds of which w

186 Advanced emphysema is a lung disease in which alveolar capillary units are destr

187 t and/or progression of chronic inflammatory lung diseases including asthma, chronic obstructive pulm

188 hysiological hallmarks of severe obstructive lung diseases including chronic obstructive pulmonary di

189 eudomonas aeruginosa colonization in chronic lung disease, including cystic fibrosis (CF) and chronic

190 uman immune cells can induce features of RSV lung disease, including mucus hyperplasia, in murine lun

191 tility of pendrin inhibitors in inflammatory lung diseases, including CF.

192 ggest involvement of pendrin in inflammatory lung diseases, including cystic fibrosis (CF), perhaps b

193 The pathogenesis of interstitial lung diseases, including its most common form, IPF, rema

194 ession in patients with CF and other chronic lung diseases, including the role respiratory viral infe

195 to SARS-CoV and how it may be implicated in lung disease induced by other highly pathogenic respirat

196 We used a transgenic mouse model of chronic lung disease induced by the overexpression of transformi

197 Allergic asthma is a chronic lung disease initiated and driven by Th2 cytokines IL-4/

198 n used for noninvasive diagnosis of a fungal lung disease (IPA) of humans, an approach with enormous

199 igate the hypothesis that flavorings-related lung disease is caused by in vivo protein damage, we cor

200 RATIONALE: Cystic fibrosis (CF) lung disease is caused by the loss of function of the cy

201 Cystic fibrosis (CF) lung disease is characterized by chronic and exaggerated

202 t diagnostic approach to diffuse parenchymal lung disease is crucial if clinical trial data are to be

203 dently of CFTR activity once cystic fibrosis lung disease is established.

204 ective surgical lung biopsy for interstitial lung disease is just under 2% but significantly higher f

205 Thus, our findings establish that fibrotic lung disease is mediated, in part, by senescent cells, w

206 The sequence of events leading to lung disease is not fully understood but recent data sho

207 inical phenotypes associated with a range of lung diseases is emerging.

208 role of the mucosal immune system in chronic lung diseases is incompletely understood.

209 nnective tissue disease-related interstitial lung disease (kappaw=0.73 [0.68-0.78]); moderate for non

210 lar disease, chronic kidney disease, chronic lung disease, liver disease, and cancer) and all-cause m

211 e (>/=70%) have higher prevalence of chronic lung disease, lower birth weight, and longer nursery sta

212 lungs indicates continuous infection in MAC lung disease (MAC-LD), but its clinical significance has

213 r disease, diabetes mellitus, liver disease, lung disease, malignancy, other organ transplantation, a

214 to understanding the pathogenesis of chronic lung disease may reside in deciphering the complex inter

215 he findings support that chronic obstructive lung diseases may have at least part of their origins in

216 entres with scleroderma-related interstitial lung disease meeting defined dyspnoea, pulmonary functio

217 STING N153S mice lacking IRF3 also developed lung disease, myeloid cell expansion, and T cell cytopen

218 ), failure to thrive (n=1), and interstitial lung disease (n=1).

219 ilzomib group (pneumonia [n=2], interstitial lung disease [n=1], septic shock [n=1], and unknown [n=1

220 Fibrotic lung diseases occur predominantly in males, and reports

221 fibrosis (IPF) is a progressive parenchymal lung disease of complex cause.

222 ional deficits routinely observed in chronic lung disease of infancy patients.

223 pleuropneumonia, an economically significant lung disease of pigs.

224 Pneumocystis pneumonia is a well-recognized lung disease of premature and malnourished babies.

225 bronchopulmonary dysplasia (BPD), a chronic lung disease of prematurity that often leads to sequelae

226 term birth, neonatal infections, and chronic lung disease of prematurity.

227 related asthma is the commonest occupational lung disease of short latency.

228 arterial hypertension (PAH) is a progressive lung disease of the pulmonary microvasculature.

229 ) is an increasingly recognized, often fatal lung disease of unknown etiology.

230 ea and cough with the absence of parenchymal lung disease on radiographic studies.

231 e lung clearance index to reflect structural lung disease on the basis of chest computed tomography a

232 -affected individuals experience progressive lung disease or cardiac and nervous system involvement (

233 re (i.e., not due to exacerbation of chronic lung disease or cardiac failure).

234 Extubation is often unsuccessful owing to lung disease or inadequate respiratory drive.

235 the two groups in the incidences of chronic lung disease or other major morbidities.

236 e heart disease, stroke, chronic obstructive lung disease, or cancer at the time they answered this b

237 clinically significant trauma, occupational lung disease, or reportable disease, and did not signifi

238 On further stratification, cavitary lung disease (P < 0.0001 for interaction) and smear stat

239 (MMP-7) has been implicated in interstitial lung disease pathobiology and proposed as a diagnostic a

240 llations and endogenous PaO2 oscillations in lung-diseased patients have different origins, it is lik

241 f invasive aspergillosis, a frequently fatal lung disease primarily affecting immunocompromised indiv

242 acterize a new subtype of congenital diffuse lung disease, provide a histological correlate, and supp

243 Forty patients with interstitial lung disease referred to our intensive care unit for acu

244 atients with cystic fibrosis (CF)-associated lung disease remains unclear.

245 The incidence of interstitial and malignant lung diseases remains unacceptably high because control

246 Diffuse parenchymal lung disease represents a diverse and challenging group

247 Allergic asthma is a chronic lung disease resulting from inappropriate immune respons

248 sitivity pneumonitis (OHP) is an immunologic lung disease resulting from lymphocytic and frequently g

249 Asthma is a complex lung disease resulting from the interplay of genetic and

250 DI, and there were no differences in chronic lung disease, retinopathy of prematurity, or NDI among s

251 composite Global Initiative for Obstructive Lung Disease scale (P < .0001).

252 ings support a role for CXCL1 and IL-8 in CF lung disease severity and identify STAT3 as a modulating

253 CXCL1 and IL8 polymorphisms with changes in lung disease severity in patients with CF (n = 6365; IL8

254 attention on the role of EHF in modifying CF lung disease severity.

255 additional genomic sites associated with CF lung disease severity.

256 et Global Initiative for Chronic Obstructive Lung Disease spirometric criteria for lung-function impa

257 in Global Initiative for Chronic Obstructive Lung Disease stage 1, where each exacerbation was associ

258 in Global Initiative for Chronic Obstructive Lung Disease stage 2 and 3 subjects.

259 D (Global Initiative for Chronic Obstructive Lung Disease stage I to II) before and after treatment w

260 D (Global Initiative for Chronic Obstructive Lung Disease stage II-IV) underwent hyperpolarized (129)

261 or Global Initiative for Chronic Obstructive Lung Disease stage.

262 D (Global Initiative for Chronic Obstructive Lung Disease) stages I-IV: 9.4, 42.5, 37.5, and 10.5%, r

263 us, cardiac, peripheral vascular and chronic lung diseases, stroke, and dementia.

264 and GenKOLS (Genetics of Chronic Obstructive Lung Disease) studies were analyzed.

265 in the CanCOLD (Canadian Cohort Obstructive Lung Disease) study, with at least 12 months of exacerba

266 sults are used for diagnosing common chronic lung diseases such as asthma and chronic obstructive pul

267 tructive pulmonary disease, and interstitial lung diseases such as idiopathic pulmonary fibrosis.

268 Applications in patients with obstructive lung diseases, such as asthma and chronic obstructive pu

269 morbidity and acute exacerbations of chronic lung diseases, such as cystic fibrosis (CF).

270 phangioleiomyomatosis (LAM) is a rare cystic lung disease that primarily affects women.

271 nent feature of asthma and other obstructive lung diseases that is minimally affected by current trea

272 e to a significant proportion of obstructive lung disease, the phenotype of obstructive lung disease

273 To appropriately investigate lung disease, the respiratory airways must be fixed in t

274 ertension due to left-sided heart disease or lung disease, the use of pulmonary vasodilator treatment

275 Unlike many other non-communicable lung diseases, the proximal causes of many occupational

276 sis for the development of this occupational lung disease through the ability of Be to induce posttra

277 ay predispose neonates with muco-obstructive lung disease to bacterial exacerbations.

278 stablished mouse model of severe obstructive lung diseases, to produce lower-mortality but pathophysi

279 characterized by vasculopathy, interstitial lung disease, ulcerative skin lesions, and premature dea

280 More than one third of patients with chronic lung disease undergoing lung transplantation have pre-ex

281 f patients who presented to the interstitial lung disease unit of the Royal Brompton and Harefield NH

282 ans were evaluated for CF-related structural lung disease using the Perth-Rotterdam Annotated Grid Mo

283 ranscripts encoded by genes implicated in CF lung disease was measured in a variety of P. aeruginosa

284 tional, and bench-based research in fibrotic lung diseases was convened.

285 Anemia, depression, and lung disease were associated with less dyspnea improveme

286 epithelial (HTBE) cells from donors without lung disease were cultured to determine pro-inflammatory

287 he metabolic syndrome, and chronic heart and lung disease were independently associated with a higher

288 gression of scleroderma-related interstitial lung disease when compared with placebo.

289 infection led to susceptibility to asthmatic lung disease when mice subsequently re-encountered aeroa

290 rated decreased reversibility of obstructive lung disease, which is atypical of asthma.

291 Idiopathic pulmonary fibrosis is a fatal lung disease with a median survival of 2 to 5 years.

292 fibrosing interstitial pneumonia, is a fatal lung disease with a median survival time of 3-5 years.

293 hanced clinical outcomes in the treatment of lung disease with cell-based therapies.

294 pulmonary fibrosis (IPF) is a chronic fatal lung disease with dismal prognosis and no cure.

295 nary fibrosis (IPF) is a chronic age-related lung disease with high mortality that is characterized b

296 nary fibrosis (IPF) is a chronic progressive lung disease with high mortality, uncertain cause, and f

297 iopathic pulmonary fibrosis is a devastating lung disease with limited treatment options.

298 (IPF) is a form of progressive interstitial lung disease with unknown etiology.

299 PD) are highly prevalent chronic obstructive lung diseases with an associated high burden of disease.

300 itial pneumonias (fIIP) are a group of fatal lung diseases with largely unknown etiology and without